Vaccine stocks tumbled Friday after the Centers for Disease Control and Prevention authorized a mix-and-match strategy for Covid booster shots. Move came with the authorization of booster shots for all recipients of the Johnson & Johnson (JNJ) vaccine and for at-risk adults who received the Moderna (MRNA) vaccination series. Moderna stock tumbled 3.8% to 326.54 after receiving a sell rating from Deutsche Bank. Fellow vaccine stock BioNTech tumbled 2.8 percent to 278.34. "IBD NewslettersGet exclusive IBD analysis and actionable news daily. Committee members backed the mix-and-match strategy to help prevent side effects in some populations. Pfizer and J&J stocks both tiptoed a fraction into the green. All adults who received the J&s;J shot are eligible for a booster two months after their first shot. Vaccine stocks have trended mostly sideways this month on worries a Covid pill from Merck will undercut immunizations. People age 65 and older, and adults who live in long-term care settings, have underlying medical conditions or work/live in high-risk settings can get a booster six months after their Moderna shots. Talbot says she hopes the clinical considerations, written recommendations accompanying each vaccine, would steer young women away from the J&J shot. Outside products from vaccine makers, companies like Regeneron Pharmaceuticals (REGN), Eli Lilly (LLY) and Vir Biotechnology (VIR) also are working on antiviral pills.
Posted by ashcrofts